OSI Pharmaceuticals Inc. and partner Genentech Inc. completed the submission of a new drug application for Tarceva, a drug for the treatment of patients with advanced non-small-cell lung cancer who have failed chemotherapy. (BioWorld Today)

Gilead Sciences Inc. walloped forecasts by posting second-quarter net income that was up 11 percent, thanks to the briskly selling HIV treatment Viread and the hepatitis B therapy Hepsera. (BioWorld Today)